

Osteoporosis Assessment Tool - OP Guidelines for postmenopausal females and males 50 years and over

1 History

☐ Initial Assessment Osteoporosis Dx: ☐ Yes ☐ No
☐ Follow-Up Previous Osteoporosis Dx: ☐ Yes ☐ No

Fracture after Age 50? ☐ Yes ☐ No [2023 Clinical Guidelines](#)

Identify risk factors for fractures and falls:

Fracture after age 50 years:	Yes	No
Hip	☐	☐
Wrist	☐	☐
Vertebral	☐	☐
Proximal humerus	☐	☐
Pelvis	☐	☐
Other, specify	☐	☐
Prolonged glucocorticoid use	☐	☐
Secondary Osteoporosis	☐	☐
Menopause at age < 45 years	☐	☐
More than 1 fragility fracture?	☐	☐
Rheumatoid Arthritis?	☐	☐
Parental history of hip fracture?	☐	☐

2 Lifestyle Review

	Yes	No
Current smoker	☐	☐
Consumes 3 units (oz.) alcohol/day	☐	☐
Has fallen 2 times in past 12 months	☐	☐
BMI <20kg/m	☐	☐
At least 150 min of moderate to vigorous physical activity/week	☐	☐
Diet + supplement calcium intake 1000 - 1200mg/day	☐	☐

[Open nutrition calculator](#)

3 Physical

A. Assess balance and gait for fracture risk:

Can patient rise from chair without using arms and walk several steps? ☐ Yes ☐ No

B. Screen for vertebral fracture:

Current height	cm		
Previous height	cm		
Prospective height loss > 2 cm	☐ Yes ☐ No	If yes to any, order PA lateral spine x-ray to rule out vert. fracture	
Historical height loss > 6 cm	☐ Yes ☐ No		
Rib-pelvis distance 2 fingers	☐ Yes ☐ No		
Occiput-wall distance > 5 cm	☐ Yes ☐ No		

4 Lab to rule out secondary osteoporosis

	Value	Target	Date of latest
Calcium			
Albumin			
Creatinine (eGFR)			
Alkaline phosphatase			
TSH			
Protein electrophoresis Only for patients with vertebral fracture	☐ Normal ☐ Abnormal		
25-hydroxyvitamin D (25OHD) if risk factors for insufficiency or starting potent antiresorptive therapy.			
CBC (Hemoglobin)			

5 Bone Mineral Density (BMD)

	Yes	No	Repeat BMD/ Reassess Fracture Risk
Prior BMD test complete	☐	☐	
BMD test ordered	☐	☐	

Vital	Latest T-score	Date
Femoral neck		
Lumbar spine		
Total hip		

If BMD test indicated, order DXA. Assess fracture risk at next apt.

6 10-year fracture risk: **FRAX** (BMD preferred)

Date Last Score

Total Hip Risk

Major Osteoporotic Fracture Risk

Category	Action
10 year fracture risk < 15% OR T-score > -2.5	Do not recommend pharmacotherapy
10 year fracture risk 15%-19.9% OR T-score -2.5 and age < 70 yrs*	Suggest pharmacotherapy Intermediate benefit
10 year fracture risk 20% OR T-score -2.5 and age 70 yr* OR 2 fragility fracture events OR Previous hip or spine fracture	Recommend pharmacotherapy Largest benefit

*femoral neck, total hip or lumbar spine

7 Recommendations for Patient Care

Recommend balance and muscle strengthening exercises at least twice per week.

Calcium through diet 1000-1200 mg daily, vitamin D3 600-800IU daily.

Falls-prevention: information provided ☐ Yes ☐ No

Strength training? ☐ Yes ☐ No

Balance exercises? ☐ Yes ☐ No

Additional risk factors to be monitored	Yes	No
Vertebral fracture identified by X-ray	☐	☐
Prior wrist fracture in patients 65 years	☐	☐
T-score much worse than -2.5 at any site	☐	☐
Lumbar T-score much worse than Femoral neck	☐	☐
Rapid bone loss	☐	☐
Men on androgen deprivation therapy	☐	☐
Women on aromatase inhibitor therapy	☐	☐
Long-term/repeat use of glucocorticoids	☐	☐
Has fallen 2 or more times in past 12 months	☐	☐
Secondary osteoporosis	☐	☐

Pharmacotherapy Recommended

Pharmacotherapy with Evidence for Fracture Prevention

	Currently On	Initiated	Changed to
Oral bisphosphonates	☐	☐	☐
IV bisphosphonates	☐	☐	☐
Denosumab	☐	☐	☐

Additional info:

Handouts: Your Guide to Strong Bones

[Ontario LU Codes](#)

CEP Falls Checklist

[Additional resources from Geras](#)



Version 3.0 (Aug 2026). Copyright ©2015

GERAS-McMaster University.
All rights reserved

